Clinical Trials
49 trialsHRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
HRYZ Biotech Co.
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
Fudan University
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
VICTORY
Melbourne Health
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Sabz Biomedicals
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
i-GO
UMC Utrecht
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
First Affiliated Hospital of Zhejiang University
NK Cell Infusion for Patients With Acute Myeloid Leukemia
Peking University People's Hospital
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors
Sun Yat-sen University
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
First Affiliated Hospital of Wenzhou Medical University
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
Xijing Hospital
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC
Guangzhou Institute of Respiratory Disease
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
Beijing Immunochina Medical Science & Technology Co., Ltd.
CyBorD-Dara
National University of Ireland, Galway, Ireland
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Safety and Efficacy Evaluation of IM19 Cells
Beijing Immunochina Medical Science & Technology Co., Ltd.
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Peking University
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Henan Cancer Hospital
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Merrimack Pharmaceuticals
Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Beijing Sanbo Brain Hospital
CD19-redirected Autologous Cells (CAR-CD19 T Cells)
RenJi Hospital
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Second People's Hospital
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Beijing Sanbo Brain Hospital
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Beva
Association Tunisienne de lutte Contre le Cancer
Study of Chemo-Immunotherapy in Head and Neck Cancer Patients
University of Yamanashi